Talphera

San Mateo, United States
Innovative therapies are developed by Talphera for medically supervised settings.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 4 Services tracked
Competitors - Brand Intelligence

About Talphera

Talphera is a company based in San Mateo (United States). It operates as a HealthTech and Licensing Model. Talphera has completed 1 acquisition, including Lowell Therapeutics. Talphera offers products and services including Niyad™, LTX-608™, Fedsyra™, and PFS-02.

  • Headquarter San Mateo, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Medical Devices & Diagnostics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Talphera

Talphera offers a comprehensive portfolio of products and services, including Niyad™, LTX-608™, Fedsyra™, and PFS-02.

Product name locked
Category locked
Primary

Regional anticoagulant developed for extracorporeal circuit in dialysis.

Product name locked
Category locked
Locked

Investigated for anti-inflammatory and antiviral therapeutic applications.

Product name locked
Category locked
Locked

Pre-filled syringe developed for hypotension treatment during anesthesia.

Product name locked
Category locked
Locked

Pre-filled syringe created for hypotension and related conditions.

People of Talphera

Headcount 50-200
Employee Profiles 4
Employee Profiles
People
Raffi Asadorian
CFO
People
Pamela P. Palmer
Chief Medical Officer and Co-Founder
People
Badri Dasu
Chief Engineering Officer
People
Vincent J. Angotti
CEO

Unlock access to complete

Funding Insights of Talphera

Premium access

Detailed funding history for Talphera

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Talphera

Talphera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Lowell Therapeutics.

Investments
Premium access

Investment portfolio details for Talphera

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Developer of anticoagulant for the treatment of acute kidney diseases
Locked Locked 2018 Locked
Premium access

Complete acquisition details for Talphera

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Talphera

Premium access

Detailed financials for Talphera

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Talphera Comparisons

Talphera Primary company
Description
Innovative therapies are developed by Talphera for medically...
Location
San Mateo, United States
Founded Year
-
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Talphera

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Talphera

Premium access

Detailed competitors of Talphera

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Talphera

Premium access

Complete news archive for Talphera

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Talphera

Talphera is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.

Innovative therapies and medical devices are developed and commercialized by Talphera for use in medically supervised settings. Focus is placed on improving patient outcomes through advanced tools for healthcare providers. Sectors include renal replacement therapy and acute care settings. Solutions such as Niyad, a regional anticoagulant for dialysis circuits, and pre-filled syringes like Fedsyra and PFS-02 are offered to enhance safety and efficiency. Additionally, LTX-608 is explored for anti-inflammatory and antiviral applications across various conditions.

Talphera offers Niyad™, LTX-608™, Fedsyra™, and PFS-02.

Talphera has made 1 acquisition, including Lowell Therapeutics.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available